Summary
Doctors writing in the Journal of the American Medical Association (JAMA) have suggested that the heart drug Natrecor was associated with increased incidence of death in clinical trials. Representatives of Scios, the manufacturer of Natrecor, have denied that the drug is dangerous. The JAMA study found that patients who took Natrecor were 80 percent more likely to die within a month than patients who took older and more affordable drugs instead. The FDA is not yet certain that Natrecor represents a danger, although FDA representatives say they are watching the debate closely. Scios has asked Harvard Medical School's Dr. Eugene Braunwald to organize a panel of independent heart experts to review the existing data.
Original source:
http://washingtontimes.com/upi-breaking/20050418-055056-3159r.htm
Details
- Washington, DC, Apr. 19 (UPI) -- A team of cardiologists said Tuesday their analysis of data on the medication Natrecor obtained from the manufacturer suggests it could be placing heart-failure patients at an increased risk of death.
- Natrecor -- generic name nesiritide -- is manufactured by Scios Inc. of Fremont, Calif., and is used for the treatment of heart-failure patients with shortness of breath.
- The current study -- based on an analysis of clinical trials conducted by Scios as well as data from the Food and Drug Administration -- found patients treated with Natrecor were 80 percent more likely to die in the month after they received the drug than those who received older and less-expensive drugs, such as nitroglycerin and diuretics.
- The latest study appears in the April 20 issue of the Journal of the American Medical Association.
- Sackner-Bernstein, who also serves as a consultant to the FDA's cardiovascular and renal drugs advisory committee, told United Press International that pooling data together from different studies is not the best way to assess mortality risk, but he added this is the best available evidence and "this is a pretty strong signal" that needs to be investigated.
- "Our full data set which includes the three studies looked at in (JAMA study) does not support the finding of these authors (of the JAMA study)," Mark Wolfe, a spokesman for Scios' parent company Johnson and Johnson, told UPI.
- Wolfe said the drug is "highly effective" for the treatment of heart failure, but added his company takes "any question about the safety of Natrecor seriously."
- For that reason, Scios has asked esteemed cardiologist Dr. Eugene Braunwald, of Harvard Medical School, to head a panel of heart experts who will review the data on the drug -- a move the company announced last week apparently in response to the Circulation article that raised the issue of kidney problems.
Related Articles
• JAMA caught red handed failing to disclose conflicts of interest, just one week after new "crackdown" announced
• Scientific medical journals like JAMA fail basic credibility standards; medical journals become increasingly irrelevant
• JAMA refuses to exclude authors who hide financial ties to drug companies
 |
Popular Topics:
JAMA, Journal of the American Medical Association, Cardiologist, Diabetes, Breast cancer, Prostate cancer, Heart disease, Depression, High cholesterol, Osteoporosis, Vaccines, Autism, ADHD, Infertility, Weight loss, Cancer, Alzheimer's, Trans fats, Acrylamides, Fluoride, Mercury |
Take Action: Support NaturalNews.com
Email this article to a friend
Share this article on: NewsVine | digg | del.icio.us
Permalink to this article: http://www.NaturalNews.com/007656.html
Reprinting this article: Non-commercial OK, cite NaturalNews.com with clickable link.
|
 |
 |
Receive our Natural Health Newsletter for FREE
Subscribe now (it's free!) to win. We randomly choose a subscriber each month to send $100 in eco-home products or a RealGoods.com gift certificate (our choice). Plus, you'll receive FREE news, articles and action alerts from NaturalNews.com editors and join over 800,000 monthly readers who report extraordinary health improvements after becoming a subscriber!
- Receive breaking news alerts on natural health solutions, renewable energy, the environment, global warming and more.
- Receive a free instant download of our $29 Secret Sources guide that reveals top sources for little-known health and diet solutions.
|
|
 |
 |
Recommended Special Report:
Seven Words that can Change the World
by Joseph R. Simonetta
Read this special report now...
"Seven Words That Can Change the World reveals the astonishing, simple truths that have the power to forever transform our world for the better while freeing our minds from the enslavement of limiting beliefs. This is not a text for the simple-minded; it is a guiding philosophy for the mindful, intelligent few who are wise enough to seek out -- and recognize -- the higher simplicities of truly purposeful living." - Mike Adams, the Health Ranger, editor of NaturalNews.com
|
More on NaturalNews.com:
• Streaming Health Ranger Videos
• CounterThink Cartoons
• FREE Special Reports
• Podcasts
|
 |
|
 |
 |
NEW 6-CD audio set reveals amazing new protocol for reversing cancer, diabetes, obesity, heart disease and more. Click to learn more. |
 |
Own the first 8 Health Ranger Report audio programs on 6 CDs. Covers weight loss, ADHD, vaccinations, processed meats, bone health and more. Click to learn more. |
Featured Videos
Short clip on Aspartame
A short clip on aspartame from the documentary All Jacked Up.
Click here to view now...
Exclusive video on Aspartame
The dangers of aspartame! Exclusive interview footage from Cori Brackett of Sweet Remedy.
Click here to view now...
Exclusive Footage from All Jacked Up!
See interview footage featuring the Health Ranger in the upcoming junk food film, All Jacked Up.
Click here to view now...
Drug Ad Parody
See the Health Ranger's satire parody of Merck's cholesterol drug ad.
Click here to view now... |
|
Read recommendations on supplement companies, health food manufacturers and personal care product makers that you can trust. Our 100% independent review list tells you who to trust and who to avoid in the natural health industry. Click to read. |
|